Dr. Alice Peng, MD

Dr. Peng practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Peng's NPI, 1790712305, was assigned on June 27, 2006. Dr. Peng graduated from David Geffen School of Medicine at UCLA in 1995. Dr. Peng holds California license A062712.

Dr. Peng's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Peng's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. Dr. Peng is also affiliated with Torrance Memorial Medical Center. The medical group on file is Cedars-Sinai Medical Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Peng practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Peng's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Peng is board certified in nephrology by the American Board of Internal Medicine. Dr. Peng is licensed in California.

Dmand AI lists acute kidney failure, chronic anemia, chronic kidney disease and parathyroid gland disorder among the conditions Dr. Peng treats.

CMS data shows 1,112 Medicare services from Dr. Peng across 10 procedure codes in 2024, for 426 Medicare patients. Medicare paid $114,745 for them.

CMS counts 426 Medicare patients who saw Dr. Peng in 2024. The largest group is under 65, with 218 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 57% are also on Medicaid. Their average risk score is 6.28, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Peng's median patient age at 60, with 40% women.

In 2024, Dr. Peng wrote 3,026 Medicare Part D claims for 397 patients. 85% of them were for generic drugs. CMS names the drug for 2,677 of them, across 44 drugs with 11 or more claims each, at $297,750 in total drug cost. In 2023, CMS named 3,093 claims across 52 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Peng for performance year 2024, reported as part of a group. Dr. Peng accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 1 paper to Dr. Peng in 2019. Dr. Peng's most frequent co-authors are Suphamai Bunnapradist, MD, Edmund Huang, MD and Stanley Jordan, MD.

Dmand AI links Dr. Peng to 2 clinical trials. Conditions studied include Delayed Graft Function and Kidney Failure, Chronic.

CMS Open Payments shows 27 general payments to Dr. Peng from 12 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 42% of the total. Pacira Pharmaceuticals Incorporated paid the most, $735.

Dr. Peng graduated from David Geffen School of Medicine at UCLA in 1995.

Dr. Peng is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.